VX1D Stock Overview
A biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Vertex Pharmaceuticals Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$373.95 |
| 52 Week High | US$399.85 |
| 52 Week Low | US$308.15 |
| Beta | 0.39 |
| 1 Month Change | -1.12% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 34.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| VX1D | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 1.0% | 1.3% |
| 1Y | n/a | -21.4% | 6.1% |
Return vs Industry: Insufficient data to determine how VX1D performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how VX1D performed against the UK Market.
Price Volatility
| VX1D volatility | |
|---|---|
| VX1D Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: VX1D has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine VX1D's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 5,400 | Reshma Kewalramani | www.vrtx.com |
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company’s pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial.
Vertex Pharmaceuticals Incorporated Fundamentals Summary
| VX1D fundamental statistics | |
|---|---|
| Market cap | €102.20b |
| Earnings (TTM) | €3.71b |
| Revenue (TTM) | €9.41b |
27.5x
P/E Ratio10.9x
P/S RatioIs VX1D overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VX1D income statement (TTM) | |
|---|---|
| Revenue | US$10.19b |
| Cost of Revenue | US$4.55b |
| Gross Profit | US$5.64b |
| Other Expenses | US$1.62b |
| Earnings | US$4.02b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 15.58 |
| Gross Margin | 55.35% |
| Net Profit Margin | 39.46% |
| Debt/Equity Ratio | 0% |
How did VX1D perform over the long term?
See historical performance and comparison